We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
OMCL saw high customer engagement around Titan XT and OmniSphere, with a larger product-bookings pipeline.
OMCL raised 2026 EBITDA guidance to $175-$185 million and EPS guidance to $2.15-$2.30 after Q2 results.
OMCL expects $6 million in incremental memory costs in second-half 2026, pressuring product gross margins.
Omnicell’s (OMCL - Free Report) autonomous pharmacy strategy aims to improve efficiency and reduce medication errors, with strong customer engagement around Titan XT and OmniSphere. The company raised its 2026 EBITDA and earnings outlook after cost discipline and operating efficiency lifted quarterly results. Omnicell’s strategic priorities include broader product adoption, recurring revenue growth and advancing OmniSphere. Yet, the company faces rising memory costs and lengthy customer approval processes that could delay Titan XT sales.
Over the past year, this Zacks Rank #3 (Hold) stock has risen 24.2% against the 5.8% fall of the industry and the 18.6% growth of the S&P 500 composite.
The renowned healthcare technology company has a market capitalization of $1.63 billion. It has an earnings yield of 6% compared to the industry’s negative 1.8% yield. Omnicell surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average earnings surprise of 47.3%.
Let’s delve deeper.
Tailwinds for OMCL Stock
Autonomous Pharmacy Model Holds Potential: The industry-defined vision of autonomous pharmacy remains a roadmap for improving operational efficiency and reducing medication-management errors. Health systems continue to face labor, cost and workflow constraints, which can delay purchasing decisions but increase the need for automation, visibility and standardized processes over time.
Omnicell has expanded from point solutions toward an enterprise medication-management platform that connects devices, data and workflows. In the second quarter of 2026, management said customer engagement around enterprise-wide medication management remained high and the product-bookings pipeline exiting the quarter was larger than in recent years. Interest has centered on Titan XT and OmniSphere as customers evaluate next-generation platforms. Omnicell also secured its first competitive Titan XT conversion win of 2026, alongside AWS, IV workflow and other solutions.
Image Source: Zacks Investment Research
Cost Discipline Supports Earnings Leverage: Omnicell continues to manage its cost structure while investing in product development. Non-GAAP EBITDA reached $67 million in the second quarter of 2026, including a one-time $15 million tariff refund. Excluding that refund, non-GAAP EBITDA would have been $52 million, still above the midpoint of prior guidance. Management attributed the underlying performance to revenue mix, cost control and operating efficiency. Following the quarter, Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $175-$185 million and non-GAAP earnings per share (EPS) guidance to $2.15-$2.30.
Strategic Imperatives to Drive Growth: Omnicell’s growth strategy continues to center on expanding its market presence, increasing recurring revenues and advancing the OmniSphere technology platform. The first pillar is broader use across inpatient and outpatient settings, including nursing units, pharmacy operations and other medication workflows. In the second quarter of 2026, existing customers selected Titan XT along with central pharmacy and inventory optimization solutions. The second pillar is a more predictable recurring revenue base through cloud-based offerings, software subscriptions and services. Service revenues reached $137 million in the second quarter of 2026, up from $127 million a year earlier.
OmniSphere is designed to unify all Omnicell products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system. The platform is also intended to support analytics and AI-driven capabilities that make workflows more predictive and efficient.
What Ails Omnicell?
Input Cost Volatility May Strain Margins: Omnicell remains exposed to cost volatility across components, supply chains and trade-related inputs. The second quarter of 2026 benefited from a one-time $15 million refund of previously paid International Emergency Economic Powers Act (IEEPA) tariffs, which lifted product gross margin and earnings, but that benefit will not recur. The company is also navigating an imbalanced supply-demand environment for memory chips. It expects this issue to add about $6 million of incremental costs in the second half of 2026, about five times the beginning-of-year cost. The impact is expected to reduce full-year 2026 consolidated gross margin by about 50 basis points (bps) and product gross margin by about 80 bps.
Younger Installed Base May Delay the Refresh Cycle: The Titan XT opportunity may develop more slowly than prior replacement cycles. Management noted that the current XT installed base is younger than what the G Series installed base was when customers transitioned from G Series to XT. This creates less urgency for some existing customers to replace functioning equipment even as Titan XT becomes available. Titan XT remains scheduled for shipment in the second half of 2026, but customers can take quarters or years to approve large capital projects. A younger fleet combined with lengthy evaluations could lengthen the replacement cycle and defer revenues that investors may otherwise expect from the new platform launch.
OMCL Stock Estimate Trend
The Zacks Consensus Estimate for Omnicell’s 2026 EPS has remained constant at $2.15 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.24 billion. This suggests a 4.4% increase from the year-ago reported number.
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have increased 2.6% against the industry’s 27.9% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 22.5% compared with the industry’s 27.9% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.6% compared with the industry’s 7.3% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
Key Takeaways
Omnicell’s (OMCL - Free Report) autonomous pharmacy strategy aims to improve efficiency and reduce medication errors, with strong customer engagement around Titan XT and OmniSphere. The company raised its 2026 EBITDA and earnings outlook after cost discipline and operating efficiency lifted quarterly results. Omnicell’s strategic priorities include broader product adoption, recurring revenue growth and advancing OmniSphere. Yet, the company faces rising memory costs and lengthy customer approval processes that could delay Titan XT sales.
Over the past year, this Zacks Rank #3 (Hold) stock has risen 24.2% against the 5.8% fall of the industry and the 18.6% growth of the S&P 500 composite.
The renowned healthcare technology company has a market capitalization of $1.63 billion. It has an earnings yield of 6% compared to the industry’s negative 1.8% yield. Omnicell surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average earnings surprise of 47.3%.
Let’s delve deeper.
Tailwinds for OMCL Stock
Autonomous Pharmacy Model Holds Potential: The industry-defined vision of autonomous pharmacy remains a roadmap for improving operational efficiency and reducing medication-management errors. Health systems continue to face labor, cost and workflow constraints, which can delay purchasing decisions but increase the need for automation, visibility and standardized processes over time.
Omnicell has expanded from point solutions toward an enterprise medication-management platform that connects devices, data and workflows. In the second quarter of 2026, management said customer engagement around enterprise-wide medication management remained high and the product-bookings pipeline exiting the quarter was larger than in recent years. Interest has centered on Titan XT and OmniSphere as customers evaluate next-generation platforms. Omnicell also secured its first competitive Titan XT conversion win of 2026, alongside AWS, IV workflow and other solutions.
Image Source: Zacks Investment Research
Cost Discipline Supports Earnings Leverage: Omnicell continues to manage its cost structure while investing in product development. Non-GAAP EBITDA reached $67 million in the second quarter of 2026, including a one-time $15 million tariff refund. Excluding that refund, non-GAAP EBITDA would have been $52 million, still above the midpoint of prior guidance. Management attributed the underlying performance to revenue mix, cost control and operating efficiency. Following the quarter, Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $175-$185 million and non-GAAP earnings per share (EPS) guidance to $2.15-$2.30.
Strategic Imperatives to Drive Growth: Omnicell’s growth strategy continues to center on expanding its market presence, increasing recurring revenues and advancing the OmniSphere technology platform. The first pillar is broader use across inpatient and outpatient settings, including nursing units, pharmacy operations and other medication workflows. In the second quarter of 2026, existing customers selected Titan XT along with central pharmacy and inventory optimization solutions. The second pillar is a more predictable recurring revenue base through cloud-based offerings, software subscriptions and services. Service revenues reached $137 million in the second quarter of 2026, up from $127 million a year earlier.
OmniSphere is designed to unify all Omnicell products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system. The platform is also intended to support analytics and AI-driven capabilities that make workflows more predictive and efficient.
What Ails Omnicell?
Input Cost Volatility May Strain Margins: Omnicell remains exposed to cost volatility across components, supply chains and trade-related inputs. The second quarter of 2026 benefited from a one-time $15 million refund of previously paid International Emergency Economic Powers Act (IEEPA) tariffs, which lifted product gross margin and earnings, but that benefit will not recur. The company is also navigating an imbalanced supply-demand environment for memory chips. It expects this issue to add about $6 million of incremental costs in the second half of 2026, about five times the beginning-of-year cost. The impact is expected to reduce full-year 2026 consolidated gross margin by about 50 basis points (bps) and product gross margin by about 80 bps.
Younger Installed Base May Delay the Refresh Cycle: The Titan XT opportunity may develop more slowly than prior replacement cycles. Management noted that the current XT installed base is younger than what the G Series installed base was when customers transitioned from G Series to XT. This creates less urgency for some existing customers to replace functioning equipment even as Titan XT becomes available. Titan XT remains scheduled for shipment in the second half of 2026, but customers can take quarters or years to approve large capital projects. A younger fleet combined with lengthy evaluations could lengthen the replacement cycle and defer revenues that investors may otherwise expect from the new platform launch.
OMCL Stock Estimate Trend
The Zacks Consensus Estimate for Omnicell’s 2026 EPS has remained constant at $2.15 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.24 billion. This suggests a 4.4% increase from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have increased 2.6% against the industry’s 27.9% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 22.5% compared with the industry’s 27.9% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.6% compared with the industry’s 7.3% growth over the past year.